09. Is this use novel or first in class?

Dronedarone is a novel drug with multi-factorial mode of action that provides for the first time for an anti-arrhythmic drug a significant reduction of the risk for cardiovascular hospitalisation or death in patients with AF/AFL, with significant reduction of cardiovascular deaths. Dronedarone also showed a favourable safety profile with a low risk for of pro-arrhythmia or organ toxicity.